4D MOLECULAR THERAPEUTICS IN (FDMT)

4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis

4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis

Conducted initial pivotal study interactions with the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA); Company has clear...

4DMT to Participate in Upcoming Investor Conferences

4DMT to Participate in Upcoming Investor Conferences

EMERYVILLE, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic...

4DMT Reports Full Year 2023 Financial Results and Operational Highlights

4DMT Reports Full Year 2023 Financial Results and Operational Highlights

Presented positive interim data from randomized Dose Expansion cohort of the Phase 2 PRISM study evaluating 4D-150 in wet AMD patients with severe disease...

4DMT Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials for Fabry Disease Cardiomyopathy at WORLDSymposium™ 2024

Investors Land FDMT 11.9% Cheaper Than Its Secondary Stock Offering

Goldman reinstates buy rating on 4D Molecular, cites upcoming catalysts (NASDAQ:FDMT)

Goldman Sachs has reinstated its buy rating on 4D Molecular Therapeutics (FDMT), citing upcoming 2024 catalysts. Read more here.

FDMT June 21st Options Begin Trading

4D Molecular Therapeutics up 3%, prices $300M equity (NASDAQ:FDMT)

4D Molecular Therapeutics announces upsized public offering of common stock and warrants, expected to raise around $300M.

4D Molecular Therapeutics Announces Pricing of Upsized Public Offering of Common Stock

4D Molecular Therapeutics Announces Pricing of Upsized Public Offering of Common Stock

EMERYVILLE, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a leading clinical-stage genetic medicines company...

4D Molecular Therapeutics files to sell mixed securities shelf (NASDAQ:FDMT)

Read about 4D Molecular Therapeutics' recent filing of a prospectus for the offer and sale of mixed securities shelf in this financial article.

4D Molecular Therapeutics launches public offering of $250M (NASDAQ:FDMT)

4D Molecular Therapeutics announces a $250M public offering of common stock, with an additional option for underwriters to buy up to $37.5M more.

4D Molecular Therapeutics Announces Proposed Public Offering of Common Stock

4D Molecular Therapeutics Announces Proposed Public Offering of Common Stock

EMERYVILLE, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a leading clinical-stage genetic medicines company...

Noteworthy Monday Option Activity: BURL, AMR, FDMT

Why Is 4D Molecular (FDMT) Stock Up 85% Today?

Investors in 4D Molecular Therapeutics and FDMT stock are seeing big gains today, as the stock surges 80% on positive trial results.

Monday Sector Leaders: Biotechnology, Semiconductors

4D Molecular stock jumps after positive interim data for eye disease drug (NASDAQ:FDMT)

Positive interim data from the Phase 2 PRISM trial of 4D-150 in wet age-related macular degeneration patients presented at a conference.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

The biggest pre-market stock movers are starting off the trading week as we check out all of the hottest news for Monday morning!

4DMT Presents Positive Interim Data from Randomized Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 Demonstrating Favorable Tolerability & Clinical Activity in Wet AMD

4DMT Presents Positive Interim Data from Randomized Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 Demonstrating Favorable Tolerability & Clinical Activity in Wet AMD

51 wet AMD patients with severe disease activity (mean of 442 µm central subfield thickness & presence of retinal fluid) and high treatment burden...